United Kingdom Research and Innovation

Medical Research Council

Shield Tx (uk) Limited

Shield Tx Ltd.

Jonathan Joseph Powell

Nuno Jorge Rodrigues Faria

Carlos André Passos Bastos

Bradley Michael Vis

Rachel Elaine Hewitt

Carlos Bastos

Laetitia Pele

Emma Thomas-McKay

Sylvaine Francoise Bruggraber

Dora Isabel Amaral Pereira

Dora I A Pereira

Nuno Jorge Rodriguez Faria

Sylvaine Francoise Aline Bruggraber

Nuno Jorge Faria

Dora IA Pereira

Compositions comprising silica particles having a mean size by standard particle sizing of between 0.5 nm and 20 nm are described for used in activating lymphocytes in culture or in whole blood.

Compositions comprising nanosilica particles and their use in methods of activating T lymphocytes for therapy

Stabilised and aquated polymeric silicate compositions are described in which the compositions are poorly condensed compositions in which the silicates are resorbable and are capable of undergoing efficient dissolution to provide bioavailable soluble silicic acid. In particular, stabilised and aquated polymeric silicates are described that are capable of intravenous delivery, useful in the treatment of cancer or systemic infection, or for topical administration, e.g. in the form of a solid or semi-solid ointment useful in the treatment of wounds or the prevention of bacterial infection.

Materials and methods relating to stabilised polymeric silicate compositions

Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.

Methods for producing carboxylate ligand modified ferric iron hydroxide colloids and related compositions and uses

The use of ferric maltol compositions for the treatment or prevention of cancer and tumours is disclosed, in particular for the treatment or prevention of gastrointestinal cancers or gastrointestinal tumours, such as large bowel (colorectal), small bowel or upper gastrointestinal cancers.

Ferric maltol compositions for use in the treatment or prevention of cancer and tumours

Methods for producing ferric maltol compositions, such as ferric trimaltol, are described in which maltolis reacted with a ligand modified ferric hydroxide and/or a ligand coated ferric hydroxide.

Methods for producing ferric maltol compositions from ligand modified and ligand coated ferric hydroxides

Methods for producing ferric maltol compositions, such as ferric trimaltol, from elemental iron, and ferric maltol compositions produced by these methods and their uses are described.

Methods for producing ferric maltol compositions from elemental iron

Copper based antibacterial agents are described based on amphiphilic copper complexes formed between copper and hydroxypyrones, such as maltol. In further aspects, the present invention relates to PEG based-ointments showing that they are particularly effective for topical delivery of amphiphilic complexes of copper. In particular, PEG ointments were shown to limit bacterial growth, even when in the absence of copper agent. However, this bacteriostatic effect is shown herein to become a true biocidal effect when copper hydroxypyrones are added to the PEG.

Antimicrobial compositions comprising copper-hydroxypyrone complexes

Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular Crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.

Amorphous magnesium-substituted calcium phosphate compositions and their uses

Methods for producing ferric maltol compositions, such as ferric trimaltol, from ferrous hydroxides, are described, as well as ferric maltol compositions produced by these methods and their uses.

Methods for producing ferric maltol compositions from ferrous hydroxides

Oxygen sensors and their uses are disclosed, and more particularly to oxygen sensors for use in product packaging for storing an article in a packaging envelope under modified atmosphere conditions wherein the oxygen sensors comprise solid oxo-hydroxy metal ion materials, optionally modified with one or more ligands and/or optionally having polymeric structures. The sensors may be present in a hydrated, oxygen permeable matrix, for example formed from a material, such as gelatine. The sensors are useful in many technical fields, and find particular application in the field of food packaging as they are safely disposable (e.g. are environmentally friendly), cheap to manufacture, and provide detectable changes in the presence of oxygen that are easy to read.

Oxygen sensors and their uses

Ligand-modified poly oxo-hydroxy metal ion materials and their uses are disclosed, in particular for nutritional, medical, cosmetic or biologically related applications for example for the treatment of a deficiency related to a component of the material or for the removal of an endogenous substance capable of binding to the material. The present invention further relates to processes for preparing the materials and optimising their physico-chemical properties and their medical uses.

Ligand modified poly oxo-hydroxy metal ion materials, their uses and processes for their preparation

Phosphate binding materials and compositions comprising them which are solid ligand-modified poly oxo-hydroxy metal ion materials are disclosed that are based on ferric iron oxo-hydroxides modified with carboxylic acid ligands, or ionized forms thereof. These materials are made and tested in the examples provided in the application to demonstrate that they can bind phosphate in in vitro and in in vivo studies.

Growing community of inventors

Cambridge, United Kingdom

Jonathan Joseph Powell